Rigel Pharmaceuticals, Inc.
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Last updated:
Abstract:
The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Status:
Grant
Type:
Utility
Filling date:
4 Mar 2019
Issue date:
25 Jan 2022